Allos Therapeutics to Report Second Quarter 2011 Results on August 4, 2011
28 7월 2011 - 9:00PM
Business Wire
Allos Therapeutics, Inc. (NASDAQ: ALTH), a biopharmaceutical
company committed to the development and commercialization of
innovative anti-cancer therapeutics, today announced that the
Company will report its financial results for the second quarter
ended June 30, 2011 on Thursday, August 4, 2011, after the
financial markets close. Following the release of the financial
results, Allos management will provide a corporate update and
review of the second quarter 2011 results via conference call and
audio webcast. Access to the conference call and webcast may be
obtained as follows:
Time: 4:30 PM ET / 2:30 PM MT
Date: Thursday, August 4, 2011
Dial-in: 1-877-941-1465 (U.S.) or +480-629-9772 (Canada and
international)
Webcast: www.allos.com (homepage and “Investors - Presentations
and Events” section)
A recorded rebroadcast will be available for interested parties
unable to attend the live conference call by dialing 1-800-406-7325
(domestic) or +1-303-590-3030 (international) and using passcode
4458751#. Webcast and telephone replays of the conference call will
be available approximately two hours after the completion of the
call through August 18, 2011.
About Allos Therapeutics
Allos Therapeutics, Inc. (Nasdaq: ALTH) is a biopharmaceutical
company committed to the development and commercialization of
innovative anti-cancer therapeutics. Allos is currently focused on
the development and commercialization of FOLOTYN® (pralatrexate
injection), a folate analogue metabolic inhibitor. FOLOTYN is
approved in the U.S. for the treatment of patients with relapsed or
refractory PTCL. For additional information, please visit
www.allos.com.
Safe Harbor Statement
The anticipated presentation will contain forward-looking
statements that involve significant risks and uncertainties.
Additional information concerning these forward-looking statements
and other factors that may cause actual results to differ
materially from those anticipated in the forward-looking statements
is contained in the "Risk Factors" section of the Company's
Quarterly Report on Form 10-Q for the quarter ended June 30, 2011
and in the Company's other periodic reports and filings with the
Securities and Exchange Commission. The Company cautions investors
not to place undue reliance on the forward-looking statements
contained in the presentation. All forward-looking statements are
based on information currently available to the Company on the date
thereof, and the Company undertakes no obligation to revise or
update these forward-looking statements to reflect events or
circumstances after the date of these presentations, except as
required by law.
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024
Allos Therapeutics, Inc. (MM) (나스닥)의 실시간 뉴스: 최근 기사 0
More Allos Therapeutics, Inc. News Articles